Drugs / BND-35
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06274437 | Jun 2024 → Apr 2026 | cancer | Biond Biologics | Terminated | No outcome recorded Stop: Business |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-10-29 | Biond Biologics | Biond Biologics Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany to Evaluate BND-35 in Combination with Cetuximab in a Phase 1 Clinical Study biondbio.com ↗ |
| 2024-06-24 | Biond Biologics | Biond Biologics Announces First Patient Dosed with BND-35 in Phase 1 Clinical Trial biondbio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BND-35 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06274437 ↗ |
| Modality | Monoclonal antibody | “Monoclonal antibody” NCT06274437 ↗ |
| Route | Intravenous | “Route of administration: Intravenous” NCT06274437 ↗ |